|
A network meta-analysis of immunotherapy-based regimens for first-line treatment of advanced non-squamous non-small cell lung cancer. |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
Travel, Accommodations, Expenses - Lilly |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
|
|
Consulting or Advisory Role - Bayer; Celgene; Lilly; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Employment - ICON Clinical Research |
Stock and Other Ownership Interests - ICON Clinical Research |
Research Funding - ICON Clinical Research (Inst) |